1. European Urology Oncology
Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting 
Shafak S. Aluwini, Niven Mehra, Martijn P. Lolkema, Daniela E. Oprea-Lager, Derya Yakar, Herman Stoevelaar, Henk van der Poel 
European Urology Oncology 
DOI: /j.euo
Copyright © 2019 European Association of Urology Terms and Conditions

2. Fig. 1
Perceived accuracy of different diagnostic modalities to assess (or diagnose) the presence (or occurrence) of OMPC, plotted against percentage of respondents. CT = computed tomography; Good = categories “very” + “extremely”; MRI = magnetic resonance imaging; OMPC = oligometastatic prostate cancer; PET = positron emission tomography; Poor = categories “not at all” + “slightly”; PSMA = prostate-specific membrane antigen.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions

3. Fig. 2
Perceived importance of different diagnostic measures for treatment decisions in patients with oligometastatic disease, plotted against percentage of respondents. Not = categories “not at all” + “slightly”; PSA = prostate-specific antigen; Very = categories: “very” + “extremely”.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions